Jennifer Uren advises direct lenders, private equity firms, and private and public company borrowers on a wide range of financing transactions.

Her experience includes direct, club, and syndicated financings, often involving cross-border components, acquisition financing for public and private companies, second lien financing and asset-based facilities.

Jennifer also has significant experience in non-dilutive life sciences financing transactions representing both companies and investors, including growth and development loans, “synthetic royalty” or revenue interest purchase transactions, drug development financings and royalty monetizations.